RELATIONSHIPS BETWEEN ESTIMATED PRICE, ACTUAL PRICE, AND RATED PRODUCT QUALITY = RELATIONS ENTRE LE PRIX ESTIME, LE PRIX REEL ET LA QUALITE SUPPOSEE DU PRODUITRECK M.1972; PSYCHOL. REP.; U.S.A.; DA. 1972; VOL. 31; NO 2; PP. 533-534; BIBL. 4REF.Article

Formally specifying an automated trade execution systemRECK, M.The Journal of systems and software. 1993, Vol 21, Num 3, pp 245-252, issn 0164-1212Article

Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (M022089) randomized phase III trialBARLESI, F; SCHERPEREEL, A; PAZZOLA, A et al.Annals of oncology. 2014, Vol 25, Num 5, pp 1044-1052, issn 0923-7534, 9 p.Article

Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancerSORIA, J.-C; MAUGUEN, A; RECK, M et al.Annals of oncology. 2013, Vol 24, Num 1, pp 20-30, issn 0923-7534, 11 p.Article

What future opportunities may immuno-oncology provide for improving the treatment of patients with lung cancer?RECK, M.Annals of oncology. 2012, Vol 23, issn 0923-7534, viii28-viii34, SUP8Article

Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upD'ADDARIO, G; FRÜH, M; RECK, M et al.Annals of oncology. 2010, Vol 21, issn 0923-7534, v116-v119, SUP5Article

SRL172 (killed Mycobacterium vaccae) in addition to standard chemotherapy improves quality of life without affecting survival, in patients with advanced non-small-cell lung cancer: phase III resultsO'BRIEN, M. E. R; ANDERSON, H; KAUKEL, E et al.Annals of oncology. 2004, Vol 15, Num 6, pp 906-914, issn 0923-7534, 9 p.Article

A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancerRECK, M; KAISER, R; ESCHBACH, C et al.Annals of oncology. 2011, Vol 22, Num 6, pp 1374-1381, issn 0923-7534, 8 p.Article

Advanced non-small cell lung cancer therapy : historical and future perspectivesRECK, M; GATZEMEIER, U.Targeted oncology. 2008, Vol 3, Num 3, pp 135-147, issn 1776-2596, 13 p.Article

Oral vinorelbine given as monotherapy to advanced, elderly NSCLC patients: a multicentre phase II trialGRIDELLI, C; MANEGOLD, C; AUBERT, D et al.European journal of cancer (1990). 2004, Vol 40, Num 16, pp 2424-2431, issn 0959-8049, 8 p.Article

Analysis of two human leukocyte antigen-linked polymorphic heat shock protein 70 genes in patients with severe sepsisSCHROEDER, S; RECK, M; HOEFT, A et al.Critical care medicine. 1999, Vol 27, Num 7, pp 1265-1270, issn 0090-3493Article

Open, randomized, multi-center phase II study comparing efficacy and tolerability of Erlotinib vs. Carboplatin/Vinorelbin in elderly patients (>70 years of age) with untreated non-small cell lung cancerHEIGENER, D. F; DEPPERMANN, K. M; RECK, M et al.Lung cancer. 2014, Vol 84, Num 1, pp 62-66, issn 0169-5002, 5 p.Article

Randomized, double-blind phase II study to compare nitroglycerin plus oral vinorelbine plus cisplatin with oral vinorelbine plus cisplatin alone in patients with stage IIIB/IV non-small cell lung cancer (NSCLC)REINMUTH, N; MEYER, A; HARTWIGSEN, D et al.Lung cancer. 2014, Vol 83, Num 3, pp 363-368, issn 0169-5002, 6 p.Article

Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trialtRECK, M; BONDARENKO, I; LUFT, A et al.Annals of oncology. 2013, Vol 24, Num 1, pp 75-83, issn 0923-7534, 9 p.Article

Randomized phase II study of cetuximab plus cisplatin/ vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancerROSELL, R; ROBINET, G; PIRKER, R et al.Annals of oncology. 2008, Vol 19, Num 2, pp 362-369, issn 0923-7534, 8 p.Article

Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancerMCKEAGE, M. J; VON PAWEL, J; CHOUAID, C et al.British journal of cancer. 2008, Vol 99, Num 12, pp 2006-2012, issn 0007-0920, 7 p.Article

Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesotheliomaMANEGOLD, C; SYMANOWSKI, J; GATZEMEIER, U et al.Annals of oncology. 2005, Vol 16, Num 6, pp 923-927, issn 0923-7534, 5 p.Article

2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced diseaseBESSE, B; ADJEI, A; FELIP, E et al.Annals of oncology. 2014, Vol 25, Num 8, pp 1475-1484, issn 0923-7534, 10 p.Article

Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upRECK, M; POPAT, S; REINMUTH, N et al.Annals of oncology. 2014, Vol 25, issn 0923-7534, iii27-iii39, SUP3Article

Randomized phase 2 trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed versus cisplatin and vinorelbine: the TREAT studyKREUTER, M; VANSTEENKISTE, J; NEUMANN, S et al.Annals of oncology. 2013, Vol 24, Num 4, pp 986-992, issn 0923-7534, 7 p.Article

Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of expertsRECK, M; BARLESI, F; CRINO, L et al.Annals of oncology. 2012, Vol 23, Num 5, pp 1111-1120, issn 0923-7534, 10 p.Article

Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)RECK, M; VON PAWEL, J; MANEGOLD, C et al.Annals of oncology. 2010, Vol 21, Num 9, pp 1804-1809, issn 0923-7534, 6 p.Article

The PstI polymorphism of the endotoxin-inducible heat-shock protein 70-2 gene does not affect messenger RNA level in human whole-blood culturesSCHROEDER, S; RECK, M; LEHMANN, L. E et al.Intensive care medicine (Print). 2000, Vol 26, Num 8, pp 1139-1143, issn 0342-4642Article

Combination chemotherapy with carboplatin, etoposide, and vincristine as first-line treatment in small-cell lung cancerGATZEMEIER, U; HOSSFELD, D. K; NEUHAUSS, R et al.Journal of clinical oncology. 1992, Vol 10, Num 5, pp 818-823, issn 0732-183XArticle

A phase II randomized study evaluating the addition of iniparib to gemcitabine plus cisplatin as first-line therapy for metastatic non-small-cell lung cancerNOVELLO, S; BESSE, B; CARCERENY, E et al.Annals of oncology. 2014, Vol 25, Num 11, pp 2156-2162, issn 0923-7534, 7 p.Article